Blair William & Co. IL reduced its stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 11.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 601,383 shares of the company's stock after selling 75,711 shares during the quarter. Blair William & Co. IL owned about 3.26% of OptimizeRx worth $2,923,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. SBI Securities Co. Ltd. acquired a new position in OptimizeRx during the fourth quarter valued at approximately $25,000. BNP Paribas Financial Markets raised its stake in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock worth $28,000 after buying an additional 2,414 shares during the period. SG Americas Securities LLC bought a new position in OptimizeRx during the fourth quarter worth about $51,000. Barclays PLC lifted its holdings in shares of OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock valued at $208,000 after purchasing an additional 21,060 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of OptimizeRx by 670.3% in the 4th quarter. JPMorgan Chase & Co. now owns 59,952 shares of the company's stock valued at $291,000 after purchasing an additional 52,169 shares during the period. 76.47% of the stock is owned by institutional investors.
Insider Activity
In other news, Director James Paul Lang bought 321,408 shares of the business's stock in a transaction that occurred on Friday, March 14th. The stock was acquired at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the purchase, the director now owns 389,452 shares of the company's stock, valued at approximately $2,959,835.20. This trade represents a 472.35 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 6.10% of the company's stock.
OptimizeRx Stock Down 7.5 %
Shares of NASDAQ:OPRX traded down $0.59 during midday trading on Friday, hitting $7.29. The stock had a trading volume of 184,496 shares, compared to its average volume of 263,137. The company has a market cap of $134.79 million, a P/E ratio of -5.48 and a beta of 1.18. OptimizeRx Co. has a 12 month low of $3.78 and a 12 month high of $14.13. The business's 50-day simple moving average is $6.49 and its 200-day simple moving average is $6.01. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on OPRX shares. JMP Securities reaffirmed a "market outperform" rating and issued a $8.00 price target on shares of OptimizeRx in a research note on Thursday, February 6th. Lake Street Capital reaffirmed a "buy" rating and issued a $11.00 target price on shares of OptimizeRx in a research note on Tuesday, December 24th. B. Riley upgraded OptimizeRx to a "strong-buy" rating in a report on Wednesday, March 12th. Royal Bank of Canada restated a "sector perform" rating and issued a $6.00 price target (down from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Finally, Stephens initiated coverage on OptimizeRx in a report on Friday, December 20th. They set an "equal weight" rating and a $5.50 price objective for the company. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $9.06.
Check Out Our Latest Research Report on OPRX
OptimizeRx Company Profile
(
Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Featured Stories
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
